Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
AssigneePfizer Inc.
InventorsJavier Gonzalez, Tanya Michelle Jewell, Hui Li, Angelica Linton, John Howard Tatlock
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).
Claims3
A compound of formula (7),
- wherein:
- R8 is hydrogen or C1-C6 alkyl;
- R12 is hydrogen or —C(O)R13;
- and
- R13 is C1-C6 alkyl or —(CH2)(C6-C10 aryl), wherein said C6-C10 aryl group is optionally substituted with at least one substituent selected from halogen, C1-C6 alkyl, —OH, —OCH3, and —N(C1-C6 alkyl)2;
- or
- a salt thereof.
A compound of formula (8),
- wherein:
- R2 is —(CR6R7)n(C6-C10 aryl) or —(CR6R7)n(5-6 membered heterocyclic), wherein said C6-C10 aryl or 5-6 membered heterocyclic group is optionally substituted with at least one R4 group;
- each R4 is independently selected from halo, —OR6, oxo, —NR6R7, —CF3, —CN, —C(O)R6, —C(O)OR6, —OC(O)R6, —NR6C(O)R7, —NR6C(O)OR7, —NR6C(O)NR6R7, —C(O)NR6R7, —SO2NR6R7—NR6SO2R7, C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl, wherein said C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl groups are optionally substituted with at least one R5;
- R5 is oxo, C3-C8 cycloalkyl, C6-C10 aryl, —OR6, —C(O)OR6, —NR6R7, —CN, and 4-10 membered heterocyclic substituted with R6;
- each R6 and R7 is independently selected from hydrogen and C1-C6 alkyl;
- R8 is hydrogen or C1-C6 alkyl;
- R12 is hydrogen or —C(O)R13;
- R13 is C1-C6 alkyl or —(CH2)(C6-C10 aryl), wherein said C6-C10 aryl group is optionally substituted with at least one substituent selected from halogen, C1-C6 alkyl, —OH, —OCH3, and —N(C1-C6 alkyl)2;
- and
- n is 0, 1, 2, 3, 4, or 5;
- or
- a salt thereof.
A compound of formula (9):
- wherein:
- R2 is —(CR6R7)n(C6-C10 aryl) or —(CR6R7)n(5-6 membered heterocyclic), wherein said C6-C10 aryl and 5-6 membered heterocyclic group is optionally substituted with at least one R4 group;
- each R4 is independently selected from halo, —OR6, oxo, —NR6R7, —CF3, —CN, —C(O)R6, —C(O)OR6, —OC(O)R6, —NR6C(O)R7, —NR6C(O)OR7, —NR6C(O)NR6R7, —C(O)NR6R7, —SO2NR6R7—NR6SO2R7, C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl, wherein said C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl groups are optionally substituted with at least one R5;
- R5 is oxo, C3-C8 cycloalkyl, C6-C10 aryl, —OR6, —C(O)OR6, —NR6R7, —CN, and 4-10 membered heterocyclic substituted with R6;
- each R6 and R7 is independently selected from hydrogen and C1-C6 alkyl;
- R8 is hydrogen or C1-C6 alkyl;
- R12 is hydrogen or —C(O)R13;
- R13 is C1-C6 alkyl or —(CH2)(C6-C10 aryl), wherein said C6-C10 aryl group is optionally substituted with at least one substituent selected from halogen, C1-C6 alkyl, —OH, —OCH3, and —N(C1-C6 alkyl)2;
- and
- n is 0, 1, 2, 3, 4, or 5;
- or
- a salt thereof.
Dependencies are inferred from the claim text.